Boston Scientific Settles With States On Guidant ICD Investigations
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific agreed Aug. 30 to pay $16.75 million to 35 states and the District of Columbia to settle investigations into the lack of public disclosure of certain defibrillator risks
You may also be interested in...
Lack Of Device Identifiers On Recalled Cardiac Devices Cost Medicare $1.5Bn, OIG Says
Medicare lost $1.5bn in claims over a 10-year period to cover procedures to fix or replace seven faulty cardiac devices due to the lack of product-specific information on its claims form for malfunctioning defibrillators and pacemakers, says the US HHS Office of Inspector General. Recalls of Medtronic, Boston Scientific and Abbott/St. Jude Medical cardiac rhythm management devices are likely behind most of the cost.
Boston Scientific settles ICD suits
Implantable cardioverter defibrillator maker will pay $195 million to settle class-action litigation stemming from a series of ICD recalls by its Guidant unit in 2005 and 2006, the company says July 13. Pending "certain conditions," the settlement will resolve nearly 4,000 individual claims that had been consolidated in the U.S. District Court for the District of Minnesota. The agreement includes an undetermined number - but not all - of additional similar claims throughout the country, the company says. Pending implementation of the agreement, trials that had been scheduled to start July 30 have been suspended (1"The Gray Sheet" June 18, 2007, In Brief)...
ICD/Pacer Advisory Standards Should Be Developed – FDA Panel Chair
Publicity surrounding recent ICD defects will spur the the Heart Rhythm Society to develop guidelines on manufacturers' advisories to physicians, FDA's Circulatory System Devices Panel chair says